Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (201-210 of 265) with videos related to

Pageof 27
Sort By:
The British Journal of Dermatology|December 31, 2024
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaJan-Malte Placke, Jenny Bottek, Renata Váraljai, et al.
European Heart Journal|August 14, 2021
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyLars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
Langenbeck'S Archives of Surgery|July 10, 2023
Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas"Jens Jakob, Dimosthenis Andreou, Jens Bedke, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastasesInes Pires da Silva, Isabel Li, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Pageof 27

Showing results (201-210 of 265) with videos related to

Sort By:
Pageof 27
The British Journal of Dermatology|December 31, 2024
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaJan-Malte Placke, Jenny Bottek, Renata Váraljai, et al.
European Heart Journal|August 14, 2021
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyLars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
Langenbeck'S Archives of Surgery|July 10, 2023
Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas"Jens Jakob, Dimosthenis Andreou, Jens Bedke, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastasesInes Pires da Silva, Isabel Li, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Pageof 27